Fig. 1
From: Cellular dormancy in minimal residual disease following targeted therapy
Identification of residual tumor cells following oncogenic pathway inhibition. a, b Carmine staining of mammary glands following oncogenic pathway inhibition in a MTB;TetO-HER2/neu and b MTB;TetO-Wnt1 models. (*) lymph node. c, d H&E-stained sections of intact c MTB;TetO-HER2/neu and d MTB;TetO-Wnt1 MRLs. e, f H&E-stained sections (left) and fluorescence microscopy of H2B-eGFP-labeled tumor cells (right) in orthotopic e HER2/neu-Prim1 and f Wnt1-Prim1 MRLs. Scale bars (a, b) 750 μm and (c–f) 250 μm